Browse Infectious Disease Articles by Topic

Reactive Hemophagocytic Syndrome in Adults

Patients with HPS were more likely to be immunosuppressed.

Peramivir for Treatment of Influenza

Peramivir (RapivabTM) was recently approved by the FDA for treating acute uncomplicated influenza.

CDC hiring IPs for Ebola jobs in West Africa

For those both compassionate and incredibly brave at heart, there are some job openings in West Africa. Though beaten back into its cage in some areas, Ebola continues to find victims in others. Infection preventionists are being asked to help.

CMS hits hospitals for high rates of infections

Hundreds of U.S. hospitals this year will revisit their infection control and safety programs in hopes of producing results that will get them out of the penalty box.

Feds lower the boom on compounding pharmacy

A 131-count criminal indictment was unsealed Dec. 17, 2014 in Boston in connection with the 2012 nationwide fungal meningitis outbreak, the U.S. Justice Department announced.

Drug Diverters May Show No Signs of Addiction

Somewhat surprisingly, drug diverters in healthcare settings are not easy to spot by outward mannerisms.

CDC: Thousands of patients put at risk by outbreaks caused by drug diverters in healthcare

Drug diversion by health care workers is gaining recognition as a ubiquitous and poorly controlled patient safety risk.

Clinical Briefs

Topics: Metformin: Have we Been Overcautious in CKD?, Reduction in Prostate, and Doing the Right Thing for Acute Bronchitis in Healthy Adults: Antibiotics

Edoxaban Tablets (Savaysa™)

The third oral factor Xa inhibitor has been approved by the FDA. Edoxaban is the fourth target-specific oral anticoagulant (TSOA) to enter the market following dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). Edoxaban is manufactured by Tokyo-based Daiichi Sankyo Company and marketed by Daiichi Sankyo as Savaysa.

The Economic Burden of Undiagnosed Pre-diabetes

The economic burden of diagnosed and undiagnosed diabetes, gestational diabetes, and prediabetes has exceeded $322 billion.